Xenoport Inc (XNPT1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Vincent J. Angotti
Employees:
214
2000 SEAPORT BLVD., SUITE 300, REDWOOD CITY, CA 94063
4086167200

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders in the United States.

Data derived from most recent annual or quarterly report
Market Cap 450.783 Million Shares Outstanding63.76 Million Avg 30-day Volume 871.937 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.2
Price to Revenue5.9421 Debt to Equity14.1696 EBITDA-71.416 Million
Price to Book Value36.2849 Operating Margin-151.59279999999998 Enterprise Value278.203 Million
Current Ratio7.578 EPS Growth-0.538 Quick Ratio7.076
1 Yr BETA 1.0726 52-week High/Low 0.0 / Profit Margin-158.5947
Operating Cash Flow Growth-79.7566 Altman Z-Score-5.508 Free Cash Flow to Firm -58.606 Million
View SEC Filings from XNPT1 instead.

View recent insider trading info

Funds Holding XNPT1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XNPT1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RIEFLIN WILLIAM JL

  • Director
No longer subject to file 2016-07-05 0

FENTON DENNIS M

  • Director
No longer subject to file 2016-07-05 0

HILLEMAN JERYL L

  • Director
No longer subject to file 2016-07-05 0

WIERENGA WENDALL

  • Director
No longer subject to file 2016-07-05 0

FREUND JOHN GORDON

  • Director
No longer subject to file 2016-07-05 0

HARRIS WILLIAM G SEE REMARKS

  • Officer
No longer subject to file 2016-07-05 0

FRIEDMAN CATHY

  • Director
No longer subject to file 2016-07-05 0

ANGOTTI VINCENT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2016-07-05 0

BATES GREGORY T SEE REMARKS

  • Officer
No longer subject to file 2016-07-05 0

RICHARD KIM SEE REMARKS

  • Officer
No longer subject to file 2016-07-05 0

BERNS PAUL L

  • Director
15,000 2016-05-17 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT CO

DEERFIELD PARTNERS, LP

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
11,572,125 2016-02-19 0

DEERFIELD PARTNERS, LP

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
75,000 2016-02-11 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT CO

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
6,320,974 2016-01-20 0

BARRETT RONALD W CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
359,942 2015-09-01 0

MARIO ERNEST

  • Director
88,750 2015-05-19 0

BOSKO GIANNA M SVP, CLO AND SECRETARY

  • Officer
92,837 2015-01-13 0

SAVELLO DAVID R SVP, DEVELOPMENT

  • Officer
0 2014-02-24 0

CUNDY KENNETH C SVP, PRECLINICAL DEVELOPMENT

  • Officer
43,851 2012-03-12 0

STAMLER DAVID A SVP, CHIEF MEDICAL OFFICER

  • Officer
7,563 2010-08-02 0

LOFBERG PER GH

  • Director
0 2010-05-11 0

GALLOP MARK A SVP, RESEARCH

  • Officer
137,857 2010-02-24 0

NUSSBACHER KENNETH J

  • Director
0 2009-05-07 0

TOLLEFSON GARY D

  • Director
0 2008-05-08 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments